Navigation Links
Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
Date:11/9/2011

DURHAM, N.C., Nov. 9, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences in New York City: the 8th Annual Lazard Healthcare Conference on November 16th at 10:30 am at The Pierre Hotel and the 23rd Annual Piper Jaffray Health Care Conference on November 29 at 11:50 am at The New York Palace.

Mr. Moch's presentation will include an update on the company's clinical pipeline, which includes its lead development program, CMX001.  CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release. Data from the ongoing placebo-controlled Phase 2 clinical trial of CMX001 in the prophylaxis of cytomegalovirus (CMV, a herpesvirus) in hematopoetic stem cell transplant patients is expected during the first quarter of 2012.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  Utilizing proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs.

The company's lead candidate, CMX001, is a lipid-antiviral-conjugate that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate.  Its broad spectrum activity against viruses without the myelotoxicity and nephrotoxicity of currently available therapies has the potential to improve outcomes for immunosuppressed patients.  CMX001 is in Phase 2 clinical development for the prophylaxis of cytomegalovirus (CMV) and the preemption and treatment of adenovirus infection in hematopoietic cell transplant recipients. Data from an ongoing, placebo-controlled Phase 2 CMV prophylaxis trial is expected during the first quarter of 2012.  In an emergency IND cohort of adenovirus-infected transplant recipients, CMX001 has demonstrated its ability to reduce viremia and improve survival.  To date, more than 650 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine.  Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. U01-A1057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.  

Chimerix's second clinical-stage antiviral compound, CMX157, is a lipid-antiviral-conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate.  CMX157 is in development as a potent nucleoside analogue against HIV and HBV infections, and has the potential to directly address several limitations of current therapies.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, providing pharmacokinetic data which support the compound's enhanced characteristics.  

Led by an experienced antiviral drug development team, Chimerix is also leveraging its lipid conjugate technology and extensive chemical library to pursue new treatments for hepatitis C virus, influenza, and other areas of high unmet medical need.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
2. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
3. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
4. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
5. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
6. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
7. Chimerix to Present at the Citi 2011 Global Health Care Conference
8. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
9. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
10. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016   GS1 US will ... guide them through GS1 Standards implementation to address the ... Unique Device Identification (UDI) rule. Scott ... Beth Gibson , senior director industry development, medical devices, ... director, GS1 US --> Scott ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from Healing ... cluster of melanin when exposed to sunlight. Although most moles are benign and harmless, ... Historically, mole removal has involved a painful, often expensive visit to the ...
Breaking Medicine News(10 mins):